MSD News
7 articles
Top Midday Gainers
PepGen (PEPG) shares experienced an increase on Thursday following the companys announcement on Wednesday that it achieved a significant milestone. The article suggests a positive impact on the companys growth, as reflected in the rise of its stock value. However, the article is part of a premium news service, requiring a subscription to access the full content. No specific details about the nature of the achievement or other business activities such as partnerships, investments, or acquisitions are provided in the available text.
Top Dividend Stocks To Consider In September 2025
The article discusses the performance of various dividend stocks amidst a market surge driven by technology stocks and strategic investments. Northeast Community Bancorp, Inc., a financial services company, offers a stable dividend yield of 3.85% with a low payout ratio. Despite reliable dividends over the past decade, recent insider selling and declining earnings forecasts raise caution. The company declared a special cash dividend of $0.20 per share, enhancing shareholder returns. Interparfums, Inc., another company mentioned, has a volatile dividend history but is covered by earnings and cash flows. Recent board changes at Interparfums bring experienced leadership, potentially benefiting its strategic direction.
Management Changes
Sector Update: Health Care Stocks Retreat Late Afternoon
The article reports a decline in healthcare stocks on Wednesday afternoon, with the NYSE Health Care Index falling by 0.8%. This decline indicates a negative impact on the healthcare sector, though specific companies are not mentioned. The article is part of a premium news service, requiring a Silver or Gold subscription to access the full content. The decline in healthcare stocks is part of broader market movements, but further details are not provided in the excerpt.
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
Stocks to watch next week: BP, Diageo, Disney, Uber and WPP
BP is set to release its second-quarter results amid declining oil and gas prices, with analysts expecting earnings of $1.35 per share and $60 billion in revenue. The company is under pressure due to weak cash flow, rising net debt, and challenges in its transition to cleaner energy sources. Activist investor Elliott has raised concerns over BPs performance, particularly its lagging shareholder returns. Analysts predict a pre-tax profit of $4.6 billion, up from $4.2 billion in Q1, but still below past levels. BPs cash flow and net debt, forecasted to be $24.9 billion by Q1 2025, remain key issues.
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the second quarter of 2025. Key developments include Mercks advancement of a Phase 1 Epstein-Barr virus vaccine trial in collaboration with OPKO, and ModeXs progress in its immuno-oncology portfolio with several clinical candidates. OPKO also presented promising preclinical data on its novel GLP-1/glucagon receptor dual agonist, OPK-88006, at the American Diabetes Associations Scientific Sessions. Additionally, OPKO is developing an oral tablet formulation of OPK-88006 in collaboration with Entera, which will be presented at the ENDO 2025 annual meeting. These advancements indicate a positive growth trajectory for OPKO Health.
Product StagePartners
